Annual report
4368.TEDINET S100VZS3
Period2024-04-01 → 2025-03-31
Filed2025-06-19
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥69.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥59.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥68.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥55.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥42.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥16.2bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥11.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥16.6bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥11.9bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥19.7bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥15.5bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.7bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥16.3bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥12.0bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥8.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.1bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥10.9bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥11.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥8.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥141.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥133.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥113.5bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥92.0bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥76.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥37.5bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥38.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥104.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥95.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥87.5bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥75.3bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥66.2bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥31.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥31.5bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥29.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.4bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥24.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥22.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.9bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥20.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥18.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.4bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥17.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥329.68 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.7 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥400.9 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥308.08 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥191.75 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,951.16 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,695.77 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,482.8 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,136.65 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,863.74 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 73.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.1% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.8% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 11.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.4% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 915 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 892 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 859 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 805 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 794 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥57.5bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥47.8bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥57.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥46.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥35.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥13.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥8.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥14.7bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥10.4bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.6bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥14.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.2bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥14.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥10.5bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥10.9bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥7.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥13.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥128.5bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥121.5bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥103.1bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥84.0bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥69.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥36.5bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥37.9bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥92.0bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥83.6bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥78.1bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥67.4bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥60.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥23.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥25.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥307.77 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥219.52 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥370.05 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥287.48 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.88 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥73 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥66 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥63 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥55 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,610.13 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,373.02 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,215.9 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,913.17 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,696.88 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 71.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.9% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.8% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 35,511,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,511,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,511,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,511,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,511,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 588 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 567 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 538 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 491 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 481 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥218m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥30.3bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥2.2bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥14.6bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥6.5bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | employees | at 2025-03-31 | 347 pure |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥33.2bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥33.2bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | segment assets | at 2025-03-31 | ¥72.6bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥13.2bn |
| Life Science Business Unitreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1.4bn |
| Life Science Business Unitreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Life Science Business Unitreportable segment | employees | at 2025-03-31 | 512 pure |
| Life Science Business Unitreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥36.3bn |
| Life Science Business Unitreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥36.3bn |
| Life Science Business Unitreportable segment | segment assets | at 2025-03-31 | ¥38.5bn |
| Life Science Business Unitreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.3bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥15.9bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥8.1bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥69.5bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥69.5bn |
| —segment total | segment assets | at 2025-03-31 | ¥111.2bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥18.5bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥291m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥208m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥31.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥2.1bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥11.6bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥5.3bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥24.8bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥24.8bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | segment assets | at 2024-03-31 | ¥63.2bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥7.5bn |
| Life Science Business Unitreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Life Science Business Unitreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Life Science Business Unitreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥34.1bn |
| Life Science Business Unitreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥34.1bn |
| Life Science Business Unitreportable segment | segment assets | at 2024-03-31 | ¥38.7bn |
| Life Science Business Unitreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥14.0bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥7.0bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥59.0bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥59.0bn |
| —segment total | segment assets | at 2024-03-31 | ¥101.9bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥13.2bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | employees | at 2025-03-31 | 334 pure |
| Life Science Business Unitreportable segment | employees | at 2025-03-31 | 198 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,601
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock fin cf | Prior1YearDuration | -744000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -631000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -2325355000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -2396208000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -10057000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -12393000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | 17663842000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -2409233000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 984005000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | -441000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 7132884000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -246366000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 22350871000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 29483756000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 29483756000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 29237390000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 6 | |
| Notes receivable trade | Prior1YearInstant | 195732000 | JPY |
| Notes receivable trade | CurrentYearInstant | 160252000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 16261977000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 15885804000 | JPY |
| Contract liabilities | Prior1YearInstant | 41083000 | JPY |
| Contract liabilities | CurrentYearInstant | 46282000 | JPY |
| Trade notes receivable transferred by endorsement | Prior1YearInstant | 29259000 | JPY |
| Trade notes receivable transferred by endorsement | CurrentYearInstant | 15399000 | JPY |
| Write downs of inventories | Prior1YearDuration | 446671000 | JPY |
| Write downs of inventories | CurrentYearDuration | 575339000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 850376000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 923886000 | JPY |
| Haulage expenses sga | Prior1YearDuration | 1600231000 | JPY |
| Haulage expenses sga | CurrentYearDuration | 1807591000 | JPY |
| Salaries and allowances sga | Prior1YearDuration | 2167676000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 2205571000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 536023000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 289456000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration | 91630000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration | 52350000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 54552000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | -76469000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | 34142983000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | 24827289000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 58970273000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 58970273000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | 34142983000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |